Table 47

Evidence addressing key question 1 for statin plus omega-3 fatty acids versus statin monotherapy comparison

OutcomesEvidence availabilityKey points of evidence synthesis
All-cause mortalityYesNo significant difference was observed for the outcome in trials in mixed populations (OR 1.08; 95% CI 0.91, 1.28)
Vascular deathNo
Fatal myocardial infarction (MI)YesNo significant difference was observed for the outcome in trials in mixed populations (OR 0.73; 95% CI 0.34, 1.58) or in participants requiring intensive lipid lowering therapy (OR 0.29; 95% CI 0.01, 7.39)
Non-fatal MIYesNo significant difference was observed for the outcome in one 240 week trial comprising of a mixed population (OR 0.75; 95% CI 0.54, 1.03)
Any or unspecified MIYesNo significant difference was observed for the outcome in one 240 week trial comprising of a mixed population (OR 0.76; 95% CI 0.56, 1.04)
Acute coronary syndrome (ACS) (encompassing unstable angina or acute MI)No
Any cerebrovascular eventNo
Hemorrhagic strokeYesNo significant difference was observed for the outcome in one 240 week trial comprising of a mixed population (OR 1.26; 95% CI 0.83, 1.91)
Ischemic strokeYesNo significant difference was observed for the outcome in one 240 week trial comprising of a mixed population (OR 0.93; 95% CI 0.72, 1.21).
Any or unspecified strokeYesNo significant difference was observed for the outcome in one 240 week trial comprising of a mixed population (OR 0.42; 95% CI 0.10, 1.87).
Transient ischemic attack (TIA)No
Carotid endarterectomy (CEA)No
Percutaneous coronary interventional procedure (PCI)No
Coronary artery bypass graft procedure (CABG)No
Any or unspecified revascularization procedureNo
Serious adverse eventsYesNo significant difference was observed for the outcome in one 8 week trial in a mixed population (OR 4.44; 0.49, 40.29)
CancerYesNo significant difference was observed for the outcome in one 240 week trial in a mixed population (OR 1.11; 0.92, 1.34).

Abbreviations: ACS = acute coronary syndrome, CABG = coronary artery bypass graft, CEA = carotid endarterectomy, MI = myocardial infarction, PCI = percutaneous coronary intervention, SAE = serious adverse event

From: 3, Results

Cover of Comparative Effectiveness of Lipid-Modifying Agents
Comparative Effectiveness of Lipid-Modifying Agents [Internet].
Comparative Effectiveness Reviews, No. 16.
Sharma M, Ansari MT, Soares-Weiser K, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.